PSO ameliorated lipid profiles, body weight, reduced hepatic steatosis/pathological damage through the in vivo experiment, and is probably associated with the potential mechanism activating the PI3K/Akt/NOS3 signaling pathway. This evidence concerns the gene AKT1 and Hepatic steatosis.